HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons

AIDS

Volumn 12, Issue 16, 1998, Pages 2125-2139

  Bernard, Nicole F ^a   Pederson, Karla ^a   Chung, Famane ^a   Ouellet, Luce ^a   Wainberg, Mark A ^b   Tsoukas, Christos M ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Asymptomatic HIV infection; Cytotoxic T lymphocytes; Non progressors; T cell subpopulations; Viral infectivity; Viral load

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CHROMIUM 51; EPITOPE; GAG PROTEIN; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; PHYTOHEMAGGLUTININ; POL PROTEIN; RNA DIRECTED DNA POLYMERASE; VIRUS ENVELOPE PROTEIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELL SPECIFICITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MEMORY CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; VACCINIA; VIRUS CELL TRANSFORMATION; VIRUS GENE; VIRUS LOAD;

ADULT; CD4-CD8 RATIO; CELLS, CULTURED; COHORT STUDIES; FEMALE; HIV; HIV INFECTIONS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RETROVIRIDAE PROTEINS; RISK FACTORS; RNA, VIRAL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL LOAD;

EID: 0032512004     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199816000-00007     Document Type: Article

References (62)

1. Lang W, Perkins H, Anderson RE, Royce R, Jewell N, Winkelstein W Jr: Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to development of AIDS. J Acquir Immune Defic Syndr 1989, 2:63-69.
2. Margolick JB, Donnenberg AD, Muñoz A, et al.: Changes in T and non-T lymphocyte subsets following seroconversion to HIV-1: stable CD3+ and declining CD3- populations suggest regulatory responses linked to loss of CD4 lymphocytes. J Acquir Immune Defic Syndr 1993, 6:153-161.
3. Yang OO, Kalams SA, Rosenzweig M, et al.: Efficient lysis of human immunodeficiency virus type 1-infected cells by cytolytic T lymphocytes. J Virol 1996, 70:5799-5806.
4. Yang OO, Kalams SA, Trocha A, et al.: Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71:3120-3128.
5. Walker CW, Moody D, Stites D, Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
6. Brinchman JE, Gaudernack G, Vartdal F: CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J Immunol 1990, 144:2961-2966.
7. Chen C-H, Weinhold K, Bartlett JA, Bolognesi DP, Greenberg ML: CD8 T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res Hum Retroviruses 1993, 9:1079-1086.
8. Mackewicz C, Levy JA: CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses 1992, 8:1039-1050.
9. Toso JF, Chen C-H, Mohr JR, et al.: Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 inhibit HIV replication. J Infect Dis 1995, 172:964-973.
10. Wiviott LD, Walker CM, Levy JA: CD8+ lymphocytes suppress HIV production by autologous CD4+ cells without eliminating the cells from culture. Cell Immunol 1990, 139:628-634.
11. Schwartz D, Sharma U, Busch M, et al.: Absence of recoverable infectious virus and unique immune responses in an asymptomatic HIV+ long-term survivor. AIDS Res Hum Retroviruses 1994, 10:1703-1711.
12. Greenough TC, Somasundaran M, Brettler DB, et al.: Normal immune function and inability to isolate virus in culture in an individual with long-term human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1994, 10:395-401.
13. Cao Y, Qin L, Zhang L, Safrit J, Ho DD: Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995, 332:201-208.
14. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC: Brief report: absence of intact nef sequences in a long-term survivor with non-progressive HIV-1 infection. N Engl J Med 1995, 332:228-232.
15. Premkumar RDR, Ma X-Z, Maitra RK, et al.: The nef gene from a long-term HIV type 1 nonprogressor. AIDS Res Hum Retroviruses 1996, 12:337-345.
16. Kestler HW, Ringler DJ, Mori K, et al.: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991, 65:651-662.
17. Rinaldo C, Huang X-L, Fan Z, et al.: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995, 69:5838-5842.
18. Harrer T, Harrer E, Kalams SA, et al.: Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. Breadth and specificity of the response and relation to in vivo viral quasispecies in a persons with prolonged infection and low viral load. J Immunol 1996, 156:2616-2623.
19. Rosenberg ES, Billingsley JM, Caliendo AM, et al.: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278:1447-1450.
20. Reddehase MJ, Jonjic S, Weiland F, Mutter M, Koszinowski UH: Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 1988, 62:1061-1065.
21. Oldstone MBA, Blount P, Southern PJ, Lampert PW: Cytoimmunotherapy for persistent virus infection reveals a unique clearance pattern from the central nervous system. Nature 1986, 321:239-243.
22. van Kuyk R, Torbett BE, Gulizia RL, Leath S, Mosier DE, Koenig S: Cloned human CD8+ cytotoxic lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J Immunol 1994, 153:4826-4833.
23. Koup RA, Safrit JT, Cao Y, et al.: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994, 68:4650-4655.
24. Burrow P, Lewicki H, Hahn RH, Shaw GM, Oldstone MRA: Virus specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus infection. J Virol 1994, 68:6103-6110.
25. Klein M, van Baalen C, Holwerda AM, et al.: Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995, 181:1365-1372.
26. Carmichael A, Jin X, Sissons P, Borysiewicz L: Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease. J Exp Med 1993, 177:249-256.
27. Zinkernagel R, Hengartner H: T-cell-mediated immunopathology versus direct cytolysis by virus: implications for HIV and AIDS. Immunol Today 1994, 15:262-268.
28. Ferbas J, Kaplan AH, Hausner MA, et al.: Virus burden in long-term survivors of human immunodeficiency virus (HIV) infection is a determinant of anti-HIV lymphocyte activity. J Infect Dis 1995, 172:329-339.
29. Dalod M, Fiorentino S, Delamare C, et al.: Delayed virus-specific CD8+ cytotoxic T lymphocyte activity in an HIV-infected individual with high CD4+ cell counts: correlation with various parameters of disease progression. AIDS Res Hum Retroviruses 1996, 12:497-506.
30. Walker BD, Chakrabarti S, Moss B, et al.: HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987, 328:345-348.
31. Walker BD, Flexner C, Paradis TJ, et al.: HIV-1 reverse transcriptase is a target for cytotoxic T-lymphocytes in infected individuals. Science 1988, 240:64-66.
32. Johnson RP, Trocha A, Yang L, et al.: HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells. J Immunol 1991, 147:1512-1521.
33. Koenig S, Fuerst TR, Wood LV, et al.: Mapping the fine specificity of a cytolytic T cell response to HIV-1 nef protein. J Immunol 1991, 145:127-135.
34. Koup RA, Pikore CA, Luzuriaga K, et al.: Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities. J Exp Med 1991, 174:1593-1600.
35. Lieberman J, Fabry JA, Kuo M-C, Earl P, Moss B, Skolnik PR: Cytotoxic T lymphocytes from HIV-1 seropositive individuals recognize immunodominant epitopes in gp160 and reverse transcriptase. J Immunol 1992, 148:2738-2747.
36. Blumberg RS, Paradis T, Byington R, Henle W, Hirsch MS, Schooley RT: Effects of human immunodeficiency virus on the cellular immune response to Epstein-Barr virus in homosexual men: characterization of the cytotoxic response and lymphokine production. J Infect Dis 1987, 155:877-890.
37. Dean M, Carrington M, Winkler C, et al.: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996, 273:1856-1862.
38. Samson M, Libert F, Doranz BJ, et al.: Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996, 382:722-725.
39. Division of AIDS, National Institutes of Allergy and Infectious Diseases American Clinical Trials Group (ACTG): Virology Manual for HIV Laboratories: National Institutes of Health Publication No. 943828. City?: NIAIDS/ACTG; 1994.
40. Kaslow RA, Carrington M, Apple R, et al.: Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996, 2:405-411.
41. Pantaleo G, Menzo S, Vaccarezza M, et al.: Studies in subjects with long-term non-progressive human immunodeficiency virus infection. N Engl J Med 1995, 332:209-216.
42. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD: Long-term HIV infection with stable CD4 levels. AIDS 1994, 8:1123-1128.
43. Sheppard HW, Lang W, Ascher MS, Wittinghoff E, Winklestein W: The characterization of non-progressors: long term HIV-1 infection with stable CD4+ T-cell levels. AIDS 1993, 7:1159-1166.
44. Hoover DR, Graham NMH, Chen B, et al.: Effect of CD4+ T cell count measurement variability on staging HIV infection. J Acquir Immune Defic Syndr 1992, 5:794-802.
45. Strathdee SA, Veugelers PJ, Page-Shafer KA, et al.: Lack of consistency between five definitions of non-progression in cohorts of HIV-infected seroconverters. AIDS 1996, 10:959-965.
46. Rammensee H-G, Friede T, Stevanovic S: MHC ligands and peptide motifs: first listing. Immunogenetics 1995, 41:178-228.
47. Nixon DF, Townsend ARM, Elvin JG, Rizza CR, Gallwey J, McMichael AJ: HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 1988, 336:484-487.
48. Huet S, Nixon DF, Rothbard JB, Townsend A, Ellis SA, McMichael AJ: Structural homologies between two HLA B27-restricted peptides suggests residues important in interaction with HLA B27. Int Immunol 1990, 2:311-316.
49. gag protein. J Virol 1993, 67:694-702.
50. Falk K, Rotzschke O, Takiguchi M, et al.: Peptide motifs of HLA-B58, B60, B61 and B62. Immunogenetics 1995, 41:165-168.
51. Gouldner P Jr, Bunce M, Krausa P, et al.: Novel, cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte epitopes in slow progressors in HIV type 1 infection. AIDS Res Human Retroviruses 1996, 12:1691-1698.
52. Arnett KL, Parham P: HLA class I nucleotide sequences. Tissue Antigens 1995, 46:217-257.
53. Falk K, Rötzschke O, Grahovac B, et al.: Allele-specific peptide ligand motifs of HLA-C molecules. Proc Natl Acad Sci USA 1993, 90:12005-12009.
54. Johnson RP, Trocha A, Buchanan TM, et al.: Recognition of a highly conserved region of human immunodeficiency virus type I gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone. J Virol 1993, 67:438-445.
55. Myers G, Hahn BH, Mellors JW, et al. (Eds): Human Retroviruses and AIDS 1995: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Los Alamos: Los Alamos National Laboratory; 1995.
56. McGuire TC, Tumas DB, Byrne KM, et al.: Major histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins. J Virol 1994, 68:1459-1467.
57. Oldstone MBA: Cytoimmunotherapy for persistent virus infection reveals a unique clearance patterns from the central nervous system. Nature 1986, 321:239-243.
58. Reusser P, Ridell SR, Meyers JD, Greenberg PD: Cytotoxic T lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991, 78:1373-1380.
59. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow transplants by transfer of T-cell clones from the donor. N Engl J Med 1995, 333:1038-1044.
60. Rooney CM, Smith CA, Ng CY, et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995, 345:9-13.
61. Yap KL, Ada GL, McKenzie IF: Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature 1978, 273:238-239.
62. van Binnerdink RS, Poelen MCM, de Vries P, et al.: Measles virus-specific human T cell clones. Characterization of specificity and function of CD4+ helper cytotoxic and CD8+ cytotoxic T cell clones. J Immunol 1989, 142:2847-2854.